Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total neoadjuvant treatment with long-course versus short-course chemoradiotherapy in rectal cancer
IRCT20230604058384N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine in rectal cancer and rectal adenocarcinoma (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Complete clinical response rate after neoadjuvant treatment. Started Aug 2023; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on IRCT20230604058384N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230604058384N1.